PA
CPRX

Profund Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Profund Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.47M Sell
46,789
-10,755
-19% -$317K 0.04% 272
2026
Q1 		$1.42M Sell
57,544
-3,532
-6% -$84.1K 0.05% 258
2025
Q4 		$1.43M Buy
61,076
+23,304
+62% +$519K 0.04% 272
2025
Q3 		$744K Buy
37,772
+12,965
+52% +$267K 0.02% 397
2025
Q2 		$538K Sell
24,807
-1,204
-5% -$28.4K 0.02% 446
2025
Q1 		$631K Sell
26,011
-1,402
-5% -$31.6K 0.03% 410
2024
Q4 		$572K Sell
27,413
-1,705
-6% -$36.6K 0.02% 445
2024
Q3 		$579K Sell
29,118
-9,842
-25% -$182K 0.02% 471
2024
Q2 		$603K Sell
38,960
-41,182
-51% -$641K 0.02% 444
2024
Q1 		$1.28M Buy
80,142
+18,578
+30% +$280K 0.05% 294
2023
Q4 		$1.03M Sell
61,564
-27,895
-31% -$381K 0.04% 322
2023
Q3 		$1.05M Sell
89,459
-43,209
-33% -$578K 0.06% 272
2023
Q2 		$1.78M Buy
132,668
+42,534
+47% +$612K 0.1% 166
2023
Q1 		$1.49M Buy
90,134
+77,524
+615% +$1.28M 0.09% 184
2022
Q4 		$235K Buy
12,610
+55
+0.4% +$847 0.02% 803
2022
Q3 		$161K Buy
+12,555
New +$149K 0.01% 849

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Profund Advisors's CPRX Position: Q2 2026 in Review

Profund Advisors reduced its Catalyst Pharmaceutical (CPRX) stake by 19% in Q2 2026, selling an estimated $317K and leaving 46,789 shares worth $1.47M. The position accounts for 0.04% of the portfolio, ranked #272.

Profund Advisors first reported a position in CPRX in Q3 2022 and has held it in 16 quarters since. The position peaked at $1.78M in Q2 2023. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Profund Advisors held 46,789 shares of Catalyst Pharmaceutical worth $1.47M as of Q2 2026.
  • Profund Advisors sold 10,755 Catalyst Pharmaceutical shares in Q2 2026, an estimated $317K.
  • Catalyst Pharmaceutical made up 0.04% of Profund Advisors's portfolio in Q2 2026, its #272 holding.
  • Profund Advisors first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 16 quarters since.
  • Profund Advisors's Catalyst Pharmaceutical position peaked at $1.78M in Q2 2023.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.